Related Experiment Video
Updated: May 9, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
The scientific rationale for long-acting biologics in dermatology
Mohamad Goldust1, Landau Marina2, Jane M Grant-Kels3
1Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, Illinois, USA.
Abstract:
The evolution of biologic therapies in dermatology increasingly emphasizes extending drug half-life to optimize pharmacokinetics and therapeutic durability. Mechanisms such as FcRn-mediated recycling, Fc engineering, albumin binding, PEGylation, and amino acid polymer technologies enhance systemic persistence and stabilize drug exposure. These advances enable sustained inhibition of key inflammatory pathways, including IL-23/T-helper 17 and IL-4/IL-13, reducing disease relapse and improving long-term outcomes. Extended half-life biologics also improve adherence, reduce immunogenicity, and lessen treatment burden through infrequent dosing. Collectively, these innovations represent a shift toward precision pharmacology, matching drug kinetics with disease biology to enhance efficacy, patient satisfaction, and health care efficiency in chronic dermatologic conditions.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Biopharmaceutics and Pharmacokinetics: Overview
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Modified-Release Drug Delivery Systems: Influencing Factors
Transdermal Drug Delivery Systems
